Posts by Peter W. PENG

The 16th Shanghai Breast Cancer Symposium and Annual Meeting of the Shanghai Anti-Cancer Association Breast Cancer Committee, hosted by the Chinese Anti-Cancer Association Breast Cancer Professional Committee (CBCS) and the Shanghai Anti-Cancer Association, and organized by the Breast Cancer Professional Committee of the Shanghai Anti-Cancer Association, was held from December 20 to 21, 2024, in Shanghai. On the afternoon of December 21, the 2025 CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines and Standards (Essentials), known as the "Little Red Book," was officially released. Oncology Frontier invited Dr. Jian Zhang, a key member of the guideline development team and expert from Fudan University Shanghai Cancer Center, to discuss updates on medical treatments for various breast cancer subtypes in the new edition.

Among breast cancer subtypes, triple-negative breast cancer (TNBC) has long been a clinical challenge due to its high malignancy and poor prognosis. Traditional therapies for advanced TNBC often yield suboptimal results, but the rise of immunotherapy has brought new hope to patients.

To advance the standard of care for gastrointestinal cancers in China and share the latest developments and insights, the "2024 CSCO Workshop on Standardized Diagnosis and Treatment of Gastrointestinal Cancers," co-hosted by the Chinese Society of Clinical Oncology (CSCO), the Beijing Xisike Clinical Oncology Research Foundation, and the Hangzhou Oriental Clinical Oncology Research Center, took place in Shanghai from August 17–18, 2024.

From December 6–8, 2024, the ESMO Asia Annual Meeting was held in Singapore, presenting groundbreaking research in oncology. Among the key highlights was the DESTINY-Gastric06 (DG06) study, which sparked extensive discussion. Oncology Frontier invited Prof. Zhi Peng, a leading researcher and specialist from Peking University Cancer Hospital, to share the latest findings from the DG06 study and insights into the role and future potential of antibody-drug conjugates (ADCs) in cancer treatment.

Pathogenic germline mutations in certain genes are known to increase the risk of hereditary breast cancer. Approximately 5% to 10% of all breast cancer cases are hereditary, primarily driven by such mutations, with BRCA1/2 being the most common. Germline mutations also guide treatment decisions, as patients with pathogenic BRCA1/2 germline mutations may benefit from PARP inhibitor-based therapies.

Treatment strategies for HR+/HER2+ breast cancer have long been a focus of research. On December 11 (Central Time), during the 47th San Antonio Breast Cancer Symposium (SABCS), the results of the TOUCH study (Abstract RF1-02) were released, drawing significant attention. This international, open-label Phase II trial explored the efficacy of a chemotherapy-free approach in the neoadjuvant treatment of early HR+/HER2+ breast cancer. Dr. Feng Jin (The First Hospital of China Medical University), Dr. Diandong Zhang (Zhongshan Hospital, Dalian University), and Dr. Xinmiao Yu (The First Hospital of China Medical University) were invited to provide in-depth commentary on the study.

The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in breast cancer research, SABCS showcases the latest research findings, clinical practices, treatment advancements, and technological innovations in breast cancer from the past year.